| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| GTO ID | GTC3573 |
| Trial ID | NCT06014762 |
| Disease | Diffuse Large B Cell Lymphoma | Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Primary Mediastinal Large B-Cell Lymphoma | Chronic Lymphocytic Leukemia |
| Altered gene | CD19|CD20 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | P-CD19CD20-ALLO1 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects With Selected Relapsed/Refractory B Cell Malignancies |
| Year | 2024 |
| Country | United States |
| Company sponsor | Poseida Therapeutics, Inc. |
| Other ID(s) | P-CD19CD20-ALLO1-001 |
| Cohort 1 | |||||||||||
|
|||||||||||